AIDS, or acquired immunodeficiency syndrome, is the final stage of untreated HIV infection, marked by extreme immune system collapse and susceptibility to opportunistic infections and cancers. It occurs when CD4 cell counts drop below 200 cells per microliter of blood.
HIV attacks CD4 T-cells, critical components of the immune system responsible for coordinating responses to pathogens. Without treatment, HIV replicates unchecked, depleting CD4 cells over years. When CD4 levels fall below 200, the body can no longer defend itself against common microbes, leading to AIDS-defining illnesses.
The Centers for Disease Control and Prevention (CDC) lists 26 conditions as AIDS-defining, including Pneumocystis pneumonia, Kaposi's sarcoma, and toxoplasmosis of the brain. These diseases rarely affect people with healthy immune systems but become life-threatening when immunity fails.
After initial HIV infection, most people experience flu-like symptoms within 2-4 weeks-fever, fatigue, swollen lymph nodes. This acute phase resolves, and the virus enters a chronic latent phase lasting years. During this time, the person may feel well but continues transmitting HIV.
Without antiretroviral therapy (ART), viral replication steadily reduces CD4 counts. The average decline is about 50 cells per microliter per year. Once CD4 drops below 200, the diagnosis of AIDS is confirmed. At this stage, the body cannot mount effective defenses against infections that normally pose little threat.
For example, Mycobacterium tuberculosis, which causes TB, typically remains dormant in 90% of infected individuals. But in people with AIDS, the reactivation rate exceeds 10% annually due to lost immune surveillance. TB is now the leading cause of death among people living with HIV globally, according to the World Health Organization (WHO).
AIDS leads to a cascade of physical and systemic failures. The most frequent complications involve the lungs, nervous system, digestive tract, and skin.
Opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP) cause persistent cough, fever, and shortness of breath. Without treatment, mortality exceeds 70%. Similarly, cryptococcal meningitis-a fungal infection of the brain-leads to confusion, headache, and coma in 30% of cases within days of onset.
Cancers associated with AIDS include Kaposi's sarcoma (skin lesions), non-Hodgkin lymphoma (lymph node swelling), and cervical cancer. These are often linked to viral co-infections: human herpesvirus 8 (HHV-8) drives Kaposi's sarcoma, while HPV increases cervical cancer risk.
Neurological effects are also common. HIV-associated neurocognitive disorders (HAND) affect up to 50% of people with AIDS, causing memory loss, slowed thinking, and motor coordination issues. Even with ART, cognitive impairment persists in 15-20% of patients, likely due to residual inflammation in the central nervous system.
| Condition | Prevalence in AIDS Patients | Key Symptoms |
|---|---|---|
| Pneumocystis pneumonia | 10-15% | Cough, fever, shortness of breath |
| Cryptococcal meningitis | 5-10% | Severe headache, confusion, vomiting |
| Kaposi's sarcoma | 10-20% | Purple skin lesions, swelling in limbs |
| Non-Hodgkin lymphoma | 5-8% | Lymph node swelling, night sweats, weight loss |
AIDS is not synonymous with HIV. A person can live with HIV for decades without progressing to AIDS if they start ART early. The CDC estimates that 95% of people diagnosed with HIV in high-income countries remain undetectable on treatment and never develop AIDS.
Some confuse AIDS with other immunodeficiencies. For example, congenital immunodeficiencies like severe combined immunodeficiency (SCID) appear in infancy and result from genetic mutations. AIDS results from a viral infection acquired later in life and is preventable through early testing and treatment.
Another misconception is that AIDS always causes rapid death. In reality, survival rates have improved dramatically since the 1990s. With consistent ART, people with AIDS can live 10-20 years beyond diagnosis. A 2021 study in The Lancet HIV found that 80% of people starting ART at CD4 counts below 200 survived five years, compared to less than 20% in the pre-ART era.
In 2003, a 34-year-old man in rural Kenya presented with a six-month history of persistent cough, fevers, and 15 kg weight loss. He had not been tested for HIV. Blood tests revealed a CD4 count of 45 cells/μL and a viral load of 500,000 copies/mL-diagnostic of AIDS.
He developed Pneumocystis pneumonia requiring mechanical ventilation. After 14 days in intensive care, he stabilized but remained severely immunocompromised. He began ART and prophylaxis for toxoplasmosis and TB. Over 18 months, his CD4 count rose to 300, and he regained strength.
This case illustrates that even advanced AIDS is treatable. Early intervention reverses many effects, though some neurological and organ damage may persist. The key factor is timely access to care-not just medication, but diagnostics, follow-up, and support.
I worked in a mobile clinic in Malawi in 2017. One patient, a woman with advanced AIDS, arrived with a swollen neck and difficulty swallowing. She had missed appointments for two years due to stigma and distance. Her CD4 was 18, viral load 1.2 million. She had disseminated tuberculosis and Kaposi's sarcoma.
She started ART and anti-TB drugs. Within three months, her lesions shrank, her appetite returned, and she resumed work. Her story underscores that progression to AIDS is not inevitable-but delay in care leads to irreversible damage. Access to testing and treatment is the difference between survival and death.
Antiretroviral therapy (ART) prevents progression to AIDS. When taken consistently, ART suppresses viral load to undetectable levels (<20 copies/mL), restoring immune function and halting transmission. The WHO recommends initiating ART regardless of CD4 count.
Early treatment reduces AIDS-related deaths by 80% and lowers the risk of serious illness by 90%, according to a 2020 meta-analysis in Journal of Infectious Diseases. People who start ART before CD4 drops below 500 have near-normal life expectancy.
Pre-exposure prophylaxis (PrEP) further reduces new infections. In South Africa, PrEP rollout reduced HIV incidence by 40% in high-risk populations over five years. Combining testing, PrEP, and ART creates a prevention cascade that stops both individual and community spread.
Understanding the effects of AIDS is not about fear-it's about action. Knowing how HIV progresses empowers individuals to test early, seek care, and stay on treatment. The effects of AIDS are not random outcomes-they are preventable consequences of delayed or absent medical intervention.